These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37864393)

  • 1. Effect of isotretinoin on CYP2D6 and CYP3A activity in patients with severe acne.
    Zhao Y; Vary JC; Yadav AS; Czuba LC; Shum S; LaFrance J; Huang W; Isoherranen N; Hebert MF
    Br J Clin Pharmacol; 2024 Mar; 90(3):759-768. PubMed ID: 37864393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 Activity.
    Amaeze OU; Czuba LC; Yadav AS; Fay EE; LaFrance J; Shum S; Moreni SL; Mao J; Huang W; Isoherranen N; Hebert MF
    J Clin Pharmacol; 2023 Mar; 63(3):363-372. PubMed ID: 36309846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
    Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
    Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
    Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
    McCune JS; Lindley C; Decker JL; Williamson KM; Meadowcroft AM; Graff D; Sawyer WT; Blough DK; Pieper JA
    J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
    Yu A; Haining RL
    Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
    Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
    Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans.
    Bedada W; de Andrés F; Engidawork E; Pohanka A; Beck O; Bertilsson L; Llerena A; Aklillu E
    J Clin Psychopharmacol; 2015 Dec; 35(6):694-9. PubMed ID: 26444948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 phenotyping with dextromethorphan.
    Wojtczak A; Rychlik-Sych M; Krochmalska-Ulacha E; Skretkowicz J
    Pharmacol Rep; 2007; 59(6):734-8. PubMed ID: 18195464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity.
    Ducharme J; Abdullah S; Wainer IW
    J Chromatogr B Biomed Appl; 1996 Mar; 678(1):113-28. PubMed ID: 8861661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.
    Funck-Brentano C; Boëlle PY; Verstuyft C; Bornert C; Becquemont L; Poirier JM
    Eur J Clin Pharmacol; 2005 Dec; 61(11):821-9. PubMed ID: 16315033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
    Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
    J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening.
    Wieling J; Tamminga WJ; Sakiman EP; Oosterhuis B; Wemer J; Jonkman JH
    Ther Drug Monit; 2000 Aug; 22(4):486-96. PubMed ID: 10942192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study.
    Spanakis M; Vizirianakis IS; Mironidou-Tzouveleki M; Niopas I
    Biomed Chromatogr; 2009 Nov; 23(11):1131-7. PubMed ID: 19444798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence.
    Leeder JS; Gaedigk A; Wright KJ; Staggs VS; Soden SE; Lin YS; Pearce RE
    Clin Transl Sci; 2022 Oct; 15(10):2514-2527. PubMed ID: 35997001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Psychopharmacol; 1999 Apr; 19(2):155-63. PubMed ID: 10211917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma.
    Chládek J; Zimová G; Beránek M; Martínková J
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):651-7. PubMed ID: 11214771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.
    Chen R; Rostami-Hodjegan A; Wang H; Berk D; Shi J; Hu P
    Eur J Pharm Sci; 2016 Sep; 92():131-6. PubMed ID: 27412587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.
    Jacqz-Aigrain E; Funck-Brentano C; Cresteil T
    Pharmacogenetics; 1993 Aug; 3(4):197-204. PubMed ID: 8220439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.